Grant to Pfizer Sample Clauses

Grant to Pfizer. Rigel hereby grants to Pfizer an exclusive, world-wide license, including the right to grant sublicenses, to research, manufacture, use, sell, offer for sale and import Licensed Products under Rigel's interest in the Product Patent Rights and the Molecular Targets.
View SourceView Similar (5)
Grant to Pfizer. Esperion hereby grants to Pfizer: (a) a worldwide, exclusive, fully paid-up license (with right to sublicense) under all Intellectual Property Controlled by Esperion or its Affiliates as of the Effective Date (including the Esperion Transferred IP but excluding the Pfizer Transferred IP) that was practiced by or on behalf of Pfizer or any of its Affiliates prior to or on the Effective Date in the conduct of the Pfizer Programs (the “Exclusive Esperion Licensed IP”), to develop, manufacture, have manufactured, sell, offer for sale, import and use the compounds or pharmaceutical products comprising compounds that arise out of the Pfizer Programs. (b) Without limiting the generality of the foregoing clause (a), a worldwide, exclusive, fully paid-up sublicense to that Intellectual Property related to the ETC-642 Pfizer Program as set forth in Schedule A, attached hereto, to develop, manufacture, have manufactured, sell, offer for sale, import and use the compounds or pharmaceutical products comprising compounds that arise out of the Pfizer Programs. CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. (c) a worldwide, non-exclusive, fully-paid up license (with right to sublicense to Affiliates without Esperion’s consent, and to Third Parties only with Esperion’s consent, not to be unreasonably withheld) to practice and use, in each case solely for research purposes, all Intellectual Property Controlled by Esperion as of the Effective Date (including the Esperion Transferred IP), including all such rights that directly relate to the ApoA-1 Target (such Intellectual Property, together with the Exclusive Esperion Licensed IP, the “Esperion Licensed IP”). Notwithstanding the foregoing, such license granted under this Section 3.1(c) shall not include the right for Pfizer, or any of its Affiliates and sublicensees, to make, have made, research, develop, use or test any of the compounds now comprising the Esperion Program or any compounds claimed under the same Patents that claim or cover the composition of matter of, or the method of making or using, ETC-1002 (the “Restricted Compounds”). Notwithstanding the foregoing restriction, Pfizer may use such Restricted Compounds as a reference standard onl...
View SourceView Similar (2)
Grant to Pfizer. 2.1.1. As of the Effective Date, subject to the terms and conditions of this Agreement, Biohaven hereby grants to Pfizer an exclusive (even as to Biohaven and its Affiliates) license under the Biohaven Patent Rights and Biohaven Know-How, with the right to grant sublicenses solely in accordance with Section 2.2 (Sublicenses), to Commercialize the Licensed Compounds and Licensed Products in the Field in the Territory. 2.1.2. As of the Effective Date, subject to the terms and conditions of this Agreement, Biohaven hereby grants to Pfizer a co-exclusive (with Biohaven and its Affiliates) license under the Biohaven Patent Rights and Biohaven Know-How, with the right to grant sublicenses solely in accordance with Section 2.2 (Sublicenses), to Develop the Licensed Compounds and Licensed Products in the Field in the Territory, including to Develop the Licensed Products in order to perform the Assumed Development Activities in the Territory. 2.1.3. As of the Effective Date, subject to the terms and conditions of this Agreement, Biohaven hereby grants to Pfizer a co-exclusive (with Biohaven and its Affiliates) license under the Biohaven Patent Rights and Biohaven Know-How, with the right to grant sublicenses solely in accordance with Section 2.2 (Sublicenses), to Manufacture the Licensed Compounds and Licensed Products in the Field in the Territory.
View Source
Grant to Pfizer. 14.1.1. As of the Effective Date, subject to the terms and conditions of this Agreement, BioShin hereby grants to Pfizer an exclusive (even as to BioShin and its Affiliates) license under the BioShin Patent Rights and BioShin Know-How, with the right to grant sublicenses solely in accordance with Section 14.2 (Sublicenses), to Commercialize the Licensed Compounds and Licensed Products in the Field in the Territory. 14.1.2. As of the Effective Date, subject to the terms and conditions of this Agreement, BioShin hereby grants to Pfizer a co-exclusive (with BioShin and its Affiliates) license under the BioShin Patent Rights and BioShin Know-How, with the right to grant sublicenses solely in accordance with Section 14.2 (Sublicenses), to Develop the Licensed Compounds and Licensed Products in the Field in the Territory, including to Develop the Licensed Products in order to perform the Assumed Development Activities in the Territory. 14.1.3. As of the Effective Date, subject to the terms and conditions of this Agreement, BioShin hereby grants to Pfizer co-exclusive (with BioShin and its Affiliates) license under the BioShin Patent Rights and BioShin Know-How, with the right to grant sublicenses solely in accordance with Section 14.2 (Sublicenses), to Manufacture the Licensed Compounds and Licensed Products in the Field in the Territory.
View Source
Grant to Pfizer. Subject to the terms and conditions of this Agreement, XOMA hereby grants to PFIZER a non-exclusive, non-transferable, worldwide license, solely within the Field, under the Patent Rights, without the right to grant sublicenses, on its own behalf to conduct Research and Development and to make, have made, use, sell, have sold, offer to sell, import and export Licensed Products, including without limitation Licensed Products arising out of a PFIZER Display System. The license granted pursuant to this Section 2.1 shall be [*] retroactive.
View Source
Grant to Pfizer 
View SourceView Similar (2)

Related to Grant to Pfizer

  • Date of Grant The date that the Option is granted (the “Date of Grant”) is set forth above.

  • Grant Date The Grant Date of the Option hereby granted is .

  • Agreement to Purchase The Seller agrees to sell, and the Purchaser agrees to purchase, on a servicing released basis (but subject to the Seller's proposed sale of servicing as provided in Section 2 and the Seller acting as a sub-servicer of the Master Servicer pursuant to a sub-servicing agreement between the Seller and the Master Servicer), the Mortgage Loans identified on the schedule (the "Mortgage Loan Schedule") annexed hereto as Exhibit 1, as such schedule may be amended to reflect the actual Mortgage Loans accepted by the Purchaser pursuant to the terms hereof. The Cut-Off Date with respect to each Mortgage Loan is such Mortgage Loan's Due Date in the month of August 2004. The Mortgage Loans and the Other Mortgage Loans will have an aggregate principal balance as of the close of business on the Cut-Off Date, after giving effect to any payments due on or before such date, whether or not received, of $65,893,090. The sale of the Mortgage Loans shall take place on August 24, 2004 or such other date as shall be mutually acceptable to the parties hereto (the "Closing Date"). The purchase price to be paid by the Purchaser for the Mortgage Loans shall equal the amount set forth as such purchase price on Exhibit 3 hereto. The purchase price shall be paid to the Seller by wire transfer in immediately available funds on the Closing Date. On the Closing Date, the Purchaser will assign to the Trustee pursuant to the Pooling and Servicing Agreement all of its right, title and interest in and to the Mortgage Loans and its rights under this Agreement (to the extent set forth in Section 14), and the Trustee shall succeed to such right, title and interest in and to the Mortgage Loans and the Purchaser's rights under this Agreement (to the extent set forth in Section 14).

  • Grant of Stock Option The Company hereby grants the Employee the Option to purchase all or any part of an aggregate number of shares of Common Stock as set forth on Schedule A (“Option Shares”) on the terms and conditions set forth herein and subject to the terms of the Plan.

  • Payment of Grant 4.1. Subject to the remainder of this paragraph 4 the Authority shall pay the Grant Recipient an amount not exceeding the total sum set out in the Grant Offer Letter. The Authority shall pay the Grant in pound sterling (GBP). 4.2. The Grant Recipient must complete and sign the Claim Form in order to receive Grant funding payments. 4.3. The signatory must be the Grant Recipient or someone with proper delegated authority on behalf of the Grant Recipient. Any change of bank details must be notified immediately and agreed by an approved signatory. Any change of signatory must be notified to the Authority for approval, as soon as known. 4.4. The Grant represents the Maximum Sum the Authority will pay to the Grant Recipient under the Funding Agreement. The Maximum Sum will not be increased in the event of any overspend by the Grant Recipient in its delivery of the Funded Activities. 4.5. The Authority will only pay the Grant to the Grant Recipient in respect of Eligible Expenditure incurred by the Grant Recipient to deliver the Funded Activities, and only up to and including the maximum sum requested in the Grant Offer Letter. The Authority will not pay the Grant until it is satisfied that the Grant Recipient has paid for the Funded Activities in full and the Funded Activities have been delivered during the Funding Period. 4.6. On request, the Grant Recipient will provide the Authority with evidence of the costs, which are classified as Eligible Expenditure in paragraph 5.2, which may include (but will not be limited to) receipts and invoices or any other documentary evidence specified by the Authority. 4.7. The Grant Recipient agrees that: 4.7.1. it will not apply for, or obtain, Duplicate Funding in respect of any part of the Funded Activities which have been paid for in full using the Grant; 4.7.2. the Authority may refer the Grant Recipient to the police should it dishonestly and intentionally obtain Duplicate Funding for the Funded Activities; 4.7.3. The Authority will not make the first payment of the Grant and/or any subsequent payments of the Grant unless or until, the Authority is satisfied that: (i) the Grant will be used for Eligible Expenditure only; and (ii) if applicable, any previous Grant payments have been used for the Funded Activities or, where there are Unspent Monies, have been repaid to the Authority. 4.8. The Grant Recipient shall submit by Grant Claim for Capital Payments (Standard Cost Items, Actual Cost Items and Additional Contributions) within three months of the End of Capital Funding Date, with a completed Claim Form and the supporting documentation as prescribed by the Authority in the EWCO Grant Manual. Where relevant, the Grant Recipient shall claim for the first five years of annual Maintenance Payments with the final Grant Claim for Capital Payments. The Grant Recipient shall claim for the second five years of annual Maintenance Payments six